5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 14.24▼ | 14.32▼ | 14.24▼ | 14.07▲ | 14.12▲ |
MA10 | 14.26▼ | 14.24▼ | 14.20▲ | 14.03▲ | 14.39▼ |
MA20 | 14.33▼ | 14.20▲ | 14.13▲ | 14.10▲ | 14.66▼ |
MA50 | 14.26▼ | 14.08▲ | 14.01▲ | 14.37▼ | 15.40▼ |
MA100 | 14.21▼ | 14.01▲ | 14.07▲ | 14.75▼ | 14.04▲ |
MA200 | 14.13▲ | 14.08▲ | 14.27▼ | 15.47▼ | 12.11▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.021▼ | 0.000▲ | 0.010▲ | 0.028▲ | -0.049▼ |
RSI | 32.024▼ | 52.982▲ | 58.021▲ | 50.417▲ | 42.542▼ |
STOCH | 4.423▼ | 54.064 | 69.132 | 45.994 | 18.753▼ |
WILL %R | -100.000▼ | -84.483▼ | -64.474 | -39.516 | -73.592 |
CCI | -133.897▼ | -6.115 | 52.710 | 141.650▲ | -50.120 |
Friday, September 26, 2025 07:46 PM
The Board of Pakistan State Oil Company Limited (PSO), the country’s largest oil marketing company (OMC), has approved the winding up of its wholly-owned subsidiary, PSO Venture Capital (Private) ...
|
Tuesday, September 23, 2025 04:14 PM
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
|
Wednesday, September 17, 2025 05:46 AM
Oruka Therapeutics (ORKA) stock rises as its lead drug ORKA-001 outperforms AbbVie's (ABBV) arthritis drug Skyrizi in Phase 1 trial. Read more here.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/10/25 | 14.395 | 14.45 | 14.205 | 14.205 | 492,858 |
30/09/25 | 14.14 | 14.195 | 14.11 | 14.16 | 433,759 |
29/09/25 | 14.10 | 14.145 | 14.07 | 14.09 | 400,471 |
26/09/25 | 13.92 | 14.00 | 13.92 | 13.99 | 283,000 |
25/09/25 | 13.93 | 13.97 | 13.86 | 13.92 | 424,100 |
24/09/25 | 13.85 | 13.93 | 13.84 | 13.88 | 465,300 |
23/09/25 | 14.05 | 14.07 | 13.83 | 13.86 | 526,100 |
22/09/25 | 14.05 | 14.11 | 14.03 | 14.09 | 477,300 |
19/09/25 | 13.98 | 14.02 | 13.95 | 13.98 | 612,300 |
18/09/25 | 14.18 | 14.22 | 14.12 | 14.14 | 629,700 |
|
|
||||
|
|
||||
|
|